A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: A preliminary study

Journal of Clinical Psychopharmacology

Volumn 32, Issue 5, 2012, Pages 593-601

  Niitsu, Tomihisa ^a   Fujisaki, Mihisa ^a   Shiina, Akihiro ^b   Yoshida, Taisuke ^a   Hasegawa, Tadashi ^b   Kanahara, Nobuhisa ^a   Hashimoto, Tasuku ^a   Shiraishi, Tetsuya ^a   Fukami, Goro ^a   Nakazato, Michiko ^a,b   Shirayama, Yukihiko ^c   Hashimoto, Kenji ^d   Iyo, Masaomi ^a,b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^d CHIBA UNIVERSITY   (Japan)

Author keywords

clinical trial; cognitive impairment; fluvoxamine; schizophrenia; sigma 1 receptor

Indexed keywords

FLUVOXAMINE; PLACEBO;

ADD ON THERAPY; ADULT; ARTICLE; ATTENTION; BLOOD EXAMINATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; ELECTROCARDIOGRAM; EXECUTIVE FUNCTION; FEMALE; HUMAN; IRRITABILITY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PARALLEL DESIGN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SCHIZOPHRENIA; SIDE EFFECT; VISUAL MEMORY; VITAL SIGN; WORKING MEMORY;

ADULT; CHRONIC DISEASE; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUVOXAMINE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; RECEPTORS, SIGMA; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865860589     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182664cfc     Document Type: Article

References (80)

1. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56(5):301-307.
2. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72(1):41-51.
3. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153(3):321-330.
4. Harvey PD, Helldin L, Bowie CR, et al. Performance-based measurement of functional disability in schizophrenia: a cross-national study in the United States and Sweden. Am J Psychiatry. 2009;166(7):821-827.
5. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158(2):176-184.
6. Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res. 2008;161(2):235-247.
7. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002; 57(2-3):209-219.
8. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007;64(6):633-647.
9. Buchanan RW, Freedman R, Javitt DC, et al. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull. 2007;33(5):1120-1130.
10. Hashimoto K. Glycine transport inhibitors for the treatment of schizophrenia. Open Med Chem J. 2010;4:10-19.
11. Hashimoto K, Koike K, Shimizu E, et al. 7 Nicotinic receptor agonists as potential therapeutic drugs for schizophrenia. Curr Med Chem CNS Agents. 2005;5:171-184.
12. Toyohara J, Hashimoto K. >7 Nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer's disease. Open Med Chem J. 2010;4:37-56.
13. Hayashi T, Su TP. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs. 2004;18(5):269-284.
14. Su TP, Hayashi T. Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem. 2003;10(20):2073-2080.
15. Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des. 2006;12(30):3857-3876.
16. Maurice T, Urani A, Phan VL, et al. The interaction between neuroactive steroids and the sigma1 receptor function: behavioral consequences and therapeutic opportunities. Brain Res Brain Res Rev. 2001;37(1-3):116-132.
17. Monnet FP, Maurice T. The sigma1 protein as a target for the non-genomic effects of neuro(active)steroids: molecular, physiological, and behavioral aspects. J Pharmacol Sci. 2006; 100(2):93-118.
18. Bermack JE, Debonnel G. The role of sigma receptors in depression. J Pharmacol Sci. 2005;97(3):317-336.
19. Guitart X, Codony X, Monroy X. Sigma receptors: biology and therapeutic potential. Psychopharmacology (Berl). 2004;174(3):301-319.
20. Ishikawa M, Hashimoto K. The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. J Receptor Ligand Channel Res. 2010;3:25-36.
21. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem. 2009;9(3):197-204.
22. Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol. 2010;25(3):193-200.
23. Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology. 2007;32(3):514-521.
24. Hashimoto K. Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia? CNS Neurol Disord Drug Targets. 2009;8(6):470-474.
25. Narita N, Hashimoto K, Tomitaka S, et al. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol. 1996;307(1):117-119.
26. Takebayashi M, Hayashi T, Su TP. Nerve growth factorYinduced neurite sprouting in PC12 cells involves sigma-1 receptors: implications for antidepressants. J Pharmacol Exp Ther. 2002; 303(3):1227-1237.
27. Nishimura T, Ishima T, Iyo M, et al. Potentiation of nerve growth factorYinduced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE. 2008;3(7):e2558.
28. Hayashi T, Su TP. Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation. Proc Natl Acad Sci USA. 2004;101(41):14949-14954.
29. Tsai SY, Hayashi T, Harvey BK, et al. Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1xGTP pathway. Proc Natl Acad Sci USA. 2009;106(52):22468-22473.
30. Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry. 2006;60(2):132-140.
31. Walterfang M, Wood SJ, Velakoulis D, et al. Neuropathological, neurogenetic and neuroimaging evidence for white matter pathology in schizophrenia. Neurosci Biobehav Rev. 2006;30(7):918-948.
32. Fields RD. White matter in learning, cognition and psychiatric disorders. Trends Neurosci. 2008;31(7):361-370.
33. Ishima T, Fujita Y, Kohno M, et al. Improvement of phencyclidineinduced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline. Open Clin Chem J. 2009;2:7-11.
34. Iyo M, Shirayama Y, Watanabe H, et al. Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(4):1072-1073.
35. Niitsu T, Shirayama Y, Fujisaki M, et al. Fluvoxamine improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1345-1346.
36. Silver H, Barash I, Aharon N, et al. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol. 2000;15(5):257-261.
37. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry. 1992;31(7):698-704.
38. Ishikawa M, Ishiwata K, Ishii K, et al. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry. 2007;62(8):878-883.
39. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
40. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982;39(7):784-788.
41. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10(3):388-398.
42. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
43. Inada T, Yagi G, Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res. 2002;57(2-3):227-238.
44. Owen AM, Downes JJ, Sahakian BJ, et al. Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia. 1990;28(10):1021-1034.
45. Levaux MN, Potvin S, Sepehry AA, et al. Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. Eur Psychiatry. 2007;22(2):104-115.
46. Fray PJ, Robbins TW. CANTAB battery: proposed utility in neurotoxicology. Neurotoxicol Teratol. 1996;18(4):499-504.
47. Sahakian BJ, Owen AM. Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J R Soc Med. 1992;85(7):399-402.
48. Faul F, Erdfelder E, Lang AG, et al. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175-191.
49. Cambridge Cognition. CANTAB Tests Spatial Working Memory (SWM). Cambridge Cognition Web site. May 18, 2011. Available at: http://www.camcog.com/en/ science/tests/swm. Accessed July 22, 2011.
50. Joyce E, Hutton S, Mutsatsa S, et al. Executive dysfunction in first-episode schizophrenia and relationship to duration of untreated psychosis: the West London Study. Br J Psychiatry Suppl. 2002;43:s38Ys44.
51. Elliott R, McKenna PJ, Robbins TW, et al. Specific neuropsychological deficits in schizophrenic patients with preserved intellectual function. Cogn Neuropsychiatry. 1998;3:45-69.
52. Pantelis C, Barber FZ, Barnes TR, et al. Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res. 1999;37(3):251-270.
53. Hiemke C, Peled A, Jabarin M, et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol. 2002;22(5):502-506.
54. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37(3):177-193.
55. D'Arrigo C, Migliardi G, Santoro V, et al. Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. Pharmacol Res. 2005;52(6):497-501.
56. Kunitachi S, Fujita Y, Ishima T, et al. Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Res. 2009;1279:189-196.
57. Erickson SK, Schwarzkopf SB, Palumbo D, et al. Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin Neuropharmacol. 2005;28(4):179-184.
58. Risch SC, Horner MD, McGurk SR, et al. Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. Schizophr Res. 2007;93(1-3):131-135.
59. Risch SC, Horner MD, McGurk SR, et al. Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder. Int J Neuropsychopharmacol. 2006;9(5):603-605.
60. Marx CE, Keefe RS, Buchanan RW, et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology. 2009;34(8):1885-1903.
61. Hashimoto K. Neurosteroid pregnenolone and sigma-1 receptor function. Clin Psychopharmacol Neurosci. 2010;8(2):115.
62. Strous RD, Maayan R, Lapidus R, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry. 2003;60(2):133-141.
63. Nachshoni T, Ebert T, Abramovitch Y, et al. Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Schizophr Res. 2005;79(2-3):251-256.
64. Strous RD, Stryjer R, Maayan R, et al. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology. 2007;32(2):96-105.
65. Ritsner MS, Gibel A, Ratner Y, et al. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychopharmacol. 2006;26(5):495-499.
66. Strous RD, Gibel A, Maayan R, et al. Hormonal response to dehydroepiandrosterone administration in schizophrenia: findings from a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol. 2008;28(4):456-459.
67. Ritsner MS, Gibel A, Shleifer T, et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry. 2010;71(10):1351-1362.
68. Ribeiz SR, Bassitt DP, Arrais JA, et al. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs. 2010;24(4):303-317.
69. Ritsner MS. Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials. CNS Neurosci Ther. 2010;16(1):32-44.
70. Sepehry AA, Potvin S, Elie R, et al. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry. 2007;68(4):604-610.
71. Takahashi H, Sugita T, Higuchi H, et al. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial. Hum Psychopharmacol. 2002;17(2):95-98.
72. Weissman AD, Casanova MF, Kleinman JE, et al. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry. 1991;29(1):41-54.
73. Helmeste DM, Tang SW, Bunney WE Jr, et al. Decrease in sigma but no increase in striatal dopamine D4 sites in schizophrenic brains. Eur J Pharmacol. 1996;314(3):R3YR5.
74. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry. 2006;67(10):e12.
75. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203-213.
76. Kern RS, Nuechterlein KH, Green MF, et al. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry. 2008;165(2):214-220.
77. Keefe RS, Goldberg TE, Harvey PD, et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68 (2-3):283-297.
78. Pietrzak RH, Olver J, Norman T, et al. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol. 2009;31(7):848-859.
79. Vinogradov S, Fisher M, Warm H, et al. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009;166(9):1055-1062.
80. Takahashi S, Sonehara K, Takagi K, et al. Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for sigma receptors. Psychopharmacology (Berl). 1999;145(3):295-302.